Abstract The purpose of this study was to determine feasibility of a novel therapeutic approach to drug-induced voiding after spinal cord injury (SCI) using a well-characterized, peptide, neurokinin 2 receptor (NK 2 receptor) agonist, Lys 5 , MeLeu 9 , Nle 10 -NKA (4-10) (LMN-NKA). Cystometry and colorectal pressure measurements were performed in urethaneanesthetized, intact, and acutely spinalized female rats. Bladder pressure and voiding were monitored in response to intravenous LMN-NKA given with the bladder filled to 70% capacity. LMN-NKA (0.1-300 μg/kg) produced dose-dependent, rapid (<60 s), short-duration (<15 min) increases in bladder pressure. In intact rats, doses above 0.3-1 μg/kg induced urine release (voiding efficiency of~70% at ≥1 μg/kg). In spinalized rats, urine release required higher doses (≥10 μg/ kg) and was less efficient (30-50%). LMN-NKA (0.1-100 μg/kg) also produced dose-dependent increases in colorectal pressure. No tachyphylaxis was observed, and the responses were blocked by an NK 2 receptor antagonist (GR159897, 1 mg/kg i.v.). No obvious cardiorespiratory effects were noted. These results suggest that rapid-onset, shortduration, drug-induced voiding is possible in acute spinal and intact rats with intravenous administration of an NK 2 receptor agonist. Future challenges remain in regard to finding alternative routes of administration that produce clinically significant voiding, multiple times per day, in animal models of chronic SCI.
Introduction
Spinal cord injury (SCI) is a traumatic condition that results in irreversible loss of sensation and voluntary control of bladder and bowel function. Acute SCI results in paralyzed or Bareflexive^bladder and bowel and inability to void. With time, individuals with injuries above the sacral level develop weak, brief, involuntary, bladder contractions, often along with bladder-sphincter dyssynergia (also known as detrusorsphincter dyssynergia or DSD), leading to urinary retention. Injuries involving the sacral cord result in a permanently areflexive bladder with predominant incontinence (de Groat and Yoshimura 2012; Panicker et al. 2015) . For bowel, injuries above the sacral level result in poor colonic motility and tightening of the sphincters and pelvic floor muscles, which leads to constipation. Injuries involving the sacral cord result in weak sphincters and pelvic floor muscles, which leads to stool incontinence (Fajardo et al. 2003; Hughes 2014) . The current standard therapy for urinary retention consists primarily of clean intermittent catheterization. While this is an effective treatment for complete bladder emptying, significant catheter-related problems occur. These include urinary tract infections, bleeding, strictures, and stones, which pose a significant health risk to the individual and account for high costs of healthcare (Cardenas et al. 2004; Gregory et al. 1984; Singh et al. 2011; Yilmaz et al. 2014) . Voiding of stools are managed by digital rectal stimulation with digital removal of stools, or with enemas, all of which are time consuming and greatly reduce the quality of life of affected individuals and caregivers (Hughes 2014) . Therefore, efficient and effective pharmacological treatments to elicit bladder and bowel emptying after SCI are imperative.
Neurokinin A (NKA), an endogenous peptide agonist for the NK 2 receptor, and NK 2 receptors themselves are expressed in the gastrointestinal and urinary bladder pathways. In vitro binding studies demonstrated the expression of NK 2 receptors in human and rodent bladder and colon smooth muscle (Burcher et al. 2000; Matuszek et al. 1998; Warner et al. 2003) . In human tissue, receptor density seems slightly higher in the colon compared to the bladder (Burcher et al. 2000; Warner et al. 2003) . In vitro contractility, studies in several species (human, rat, hamster) demonstrated NK 2 receptormediated contraction of the bladder (Giuliani et al. 1993; Palea et al. 1996; Quinn et al. 2004; Tramontana et al. 1998; Warner et al. 2003 ) and gastrointestinal tract (Carini et al. 2001; Lecci et al. 2004 Lecci et al. , 2006 Mule et al. 2000) . Moreover, the NK 2 receptor-mediated bladder contractions in human SCI-induced neurogenic overactive detrusor strips were similar to those from detrusor tissue taken from normal individuals (Sellers et al. 2006) . In vivo experiments in anesthetized animals (rat, hamster, guinea pig) report that NK 2 receptor agonists (NKA, ]NKA (4-10) , Lys 5 , MeLeu 9 , Nle 10 -NKA (4-10) ) produce an increase in bladder contractility, baseline tone, and distension evoked responses (Kullmann et al. 2013; Maggi et al. 1986 Maggi et al. , 1987 Tramontana et al. 1998 ). Enhancement of neuronally evoked contractions in response to NK 2 receptor stimulation was also reported, suggesting that efferent neuronal activity may be augmented (Maggi et al. 1986; Tramontana et al. 1998) . Additionally, NK 2 receptor activation may lower the threshold for triggering micturition by increasing the excitability of primary afferent neurons (primarily C-fibers) innervating the bladder (Maggi et al. 1986 (Maggi et al. , 1987 Morrison et al. 1999; Sculptoreanu et al. 2008 Sculptoreanu et al. , 2009 Sculptoreanu and de Groat 2003) .
Animal studies investigating in vivo gastrointestinal motility have shown increased activity after stimulation of NK 2 receptors (Carini et al. 2001; Lecci et al. 2004 Lecci et al. , 2006 Lordal et al. 1997 Lordal et al. , 2001 Mule et al. 2000; Warner et al. 2003) . These effects are thought to be mediated by a direct action on circular smooth muscle with a possible modulatory effect on cholinergic nerves (Lecci et al. 2004 (Lecci et al. , 2006 . Most importantly, human volunteer studies demonstrated that intravenous infusion of exogenous NKA (6, 12, 25, and 50 pm/kg/min for 4 h) produced dose-dependent increases in gastrointestinal motility mediated by NK 2 receptors, with a good tolerability and safety profile (Lordal et al. 1997 (Lordal et al. , 2001 Schmidt et al. 2003) . Together, these studies suggest that activation of NK 2 receptors has the potential to trigger contractions of the bladder and colon and could induce voiding after SCI.
The present study explores in vivo pharmacodynamic characteristics of NK 2 receptor-induced activation of the bladder and colon using Lys 5 , MeLeu 9 , Nle 10 -NKA (4-10) (LMN-NKA), as a tool to determine feasibility of this novel therapeutic approach to drug-induced voiding.
Materials and methods
Animals Adult, female, Sprague-Dawley rats (230-300 g, n = 67, Charles River, Raleigh, NC) were maintained under standard laboratory housing conditions with free access to water and food. All experiments were performed in accordance with the NIH Guidelines for the Care and Use of Laboratory Animals and approved by the Integrated Laboratory Systems animal care and use committee. All efforts were made to minimize animal stress and to reduce the number of animals used.
Surgical procedures Rats were anesthetized with urethane (1.2-1.4 g/kg urethane s.c.) and body temperature was maintained at 37°C by a heated blanket. The carotid artery and jugular vein were cannulated to allow blood pressure measurements and intravenous (i.v.) drug delivery, respectively. The abdomen was opened, and the ureters were ligated and cut distally. Saline-filled polyethylene tubing with a flared tip (PE 50) was inserted through a small incision in the dome of the bladder and tied in place. Colorectal pressure was measured in a separate group of animals. The lower gastrointestinal tract and rectum were cleared of feces and a balloon catheter (2.5 cm length, made using the tip of a Trojan ENZ nonlubricated condom attached to PE50 tubing and a 20G blunt needle) was placed approximately 3-4 cm into the rectum, through the anus. The bladder or colorectal cannulas were connected to a T-tube, for saline infusion (room temperature, PHD2000 infusion pump, Harvard Apparatus, Holliston, MA, USA) and measurement of bladder or colorectal pressure (CDXIII Transducer). The signal was amplified using a bridge amplifier (Transbridge 4M, world precision instruments). Animals were either spinally intact or, 1 h prior to study, received a complete spinal cord transection at the T9-T10 level after exposure of the vertebrae and a laminectomy (Tanahashi et al. 2012) .
Drugs All drugs were purchased from Tocris (Bristol, UK -NKA (4-10) (NK 2 receptor agonist, LMN-NKA), and spantide I (NK 1 receptor antagonist) were dissolved in saline, and [bAla8]-Neurokinin A(4-10) (NK 2 receptor agonist) was solubilized in water or saline. GR159897 (NK 2 receptor antagonist) was solubilized at 50 mM in DMSO and diluted with saline to a concentration of 1 mg/ml (2.4 mM). Final DMSO concentration was 4.8%. All drugs were administered intravenously and followed by 0.3 ml saline flush. In antagonist studies, LMN-NKA (10 or 30 μg/kg) was given before and 5 min after each antagonist (1 mg/kg) and responses compared.
Isovolumetric cystometry was conducted in acute SCI rats. To determine functional bladder capacity (Fig. 1) , the bladder was emptied and a cystometrogram (CMG) performed with the urethra opened (infusion rate 0.06-0.1 ml/min). The volume necessary to fill the bladder from an empty state to the threshold volume for triggering leaking in spinalized animals was measured. This process was repeated three to six times per rat; the volumes were averaged and taken as the functional bladder capacity. For drug testing, the urethra was clamped externally at the meatus, and the bladder filled to 70% of functional bladder capacity where it remained throughout the experimental procedure. Each rat was given saline vehicle and then ascending doses of LMN-NKA (0.01-300 μg/kg). The time between dosing was 15-45 min to allow the bladder to return to a stable pressure.
Voiding cystometry (Kullmann et al. 2014 ) was performed ( Fig. 1) as described above to determine each rat's bladder capacity and bladder pressure during voiding (intact rats) or the leak point pressure (acute SCI rats). The bladder infusion rate (0.04-0.1 ml/min) was adjusted for each animal to reach bladder capacity within~10-15 min and maintained constant throughout the experiment. For drug testing, the bladder was filled to 70% of functional bladder capacity, the infusion pump turned off, and the rat dosed with the vehicle. After 5 min, in which the vehicle's effects were monitored, the bladder was emptied and voided volume (if any) and residual volume measured. The infusion pump was restarted and distensioninduced contractions were observed for 20-60 min to allow the bladder to return to control voiding/leaking characteristics. This cycle was repeated with ascending doses of LMN-NKA (0.1-300 μg/kg), according to the protocol outlined in Fig. 1 .
Parameters measured Maximal bladder pressure, bladder pressure response (maximal bladder pressure minus baseline pressure), time from injection to peak bladder pressure (time to peak), duration of action (time from injection to return to within 5 mmHg of pretreatment bladder pressure), voided volume (VV), residual volume (RV), and voiding efficiency (VE), calculated as ((VV / (VV + RV)) * 100%), were measured. In addition, the voiding responder rate was calculated as the percentage of rats voiding >0.03 ml divided by total number of rats/group * 100%.
Colorectal activity A colorectal balloon catheter was inflated by incrementally adding 0.1 ml saline until a steady pressure reading of 15-20 mmHg was obtained (total volume 0.3-0.7 ml). Once the colorectal pressure was stable, dosing of vehicle, followed by ascending log doses of LMN-NKA Fig. 1 Schematic of experimental design. a The experiment is divided into three main blocks: establishment of baseline voiding parameters, determination of functional bladder capacity, and investigation of drug effects. First, cystometry is performed for 20-60 min to establish baseline voiding parameters. Next, functional bladder capacity is determined as follows b: the bladder is emptied and a cystometrogram (CMG) is started. When the rats void (intact) or start leaking (acutely spinalized), the infusion pump is stopped and the infused, voided, and residual volumes are measured. The process is repeated three times and the infused volume necessary to trigger voiding or leaking is averaged and termed 100% functional bladder capacity. c The last block determines drug effects. For this, the bladder is filled to 70% capacity, the infusion pump is stopped and vehicle or drug are given i.v. Five minutes following vehicle/drug dosing, voided (VV) and residual (RV) volumes are measured. The infusion pump is then turned on and a period of at least 20 min is allowed for recovery prior to next drug dose (0.1-100 μg/kg i.v.) was administered. The time between drug doses was approximately 20-45 min.
Parameters measured As the gastrointestinal tract presents intrinsic activity that is tonic in nature and drug effects are superimposed on this tonic activity, two measurements were chosen:
1. Area under the curve (AUC), which reflects tonic and drug-induced activity, and 2. Duration of action (min) following drug administration.
This measure is a close approximation of drug-induced activity. The threshold amplitude of the colonic activity was chosen at 5 mmHg, which was the average amplitude of spontaneous pressure fluctuations during control periods.
Selectivity of the NK 2 receptor agonist To explore the effects of spantide I, an NK 1 receptor antagonist, and GR159897, an NK 2 receptor antagonist, on the LMN-NKAinduced increase in bladder pressure and colorectal activity, the animals received a 10 or 30 μg/kg i.v. dose of LMN-NKA before, and 5 min after, each antagonist (1 mg/kg for each antagonist). Responses to LMN-NKA (10 or 30 μg/kg, i.v.) were compared before and after antagonist treatment.
Data analysis and statistics Data were recorded using LabChart software (version 7; ADInstruments, Australia) and analyzed using Excel (Microsoft, Redmond, WA) and Prism 6 (GraphPad Software Inc., San Diego, CA). Data are presented as mean and standard deviation. One-way ANOVA with Dunnett's multiple comparison post-test or paired Student's t test was used, as appropriate; p < 0.05 was considered statistically significant.
Results
Onset and duration of action, tachyphylaxis examination, and involvement of the NK 2 receptor in LMN-NKA effects on bladder function (isovolumetric cystometry) in acute spinal rats
To determine the effects of LMN-NKA on bladder contractility, acute SCI rats were dosed with ascending doses of the drug, 0.1-100 μg/kg i.v. (n = 4-16 rats per group). Under isovolumetric conditions with the bladder filled to 70% capacity, LMN-NKA produced dose-dependent bladder contractions (Fig. 2a, b) . At doses ≤1 μg/kg, contractions were monophasic with a rapid rise to peak at~40 s and a gradual return to baseline within 15 min. At higher doses, a biphasic response was observed that consisted of 1 or 2 immediate, rapid spikes in pressure that seemed to be superimposed on the gradual contraction seen at lower doses (Fig. 2a) . Druginduced bladder contractions returned to baseline levels within 15-20 min depending on the dose (Fig. 2c) . Similar effects were observed with the NK 2 receptor specific agonist, [βAla 8 ]-NKA (4) (5) (6) (7) (8) (9) (10) , and with NKA (data not shown). The selectivity of the effects of LMN-NKA for NK 2 receptors was examined by using the specific NK 2 receptor antagonist, GR159897. GR159897 (1 mg/kg i.v.) significantly inhibited the maximal bladder pressure induced by LMN-NKA (Table 1) . Bladder contractions were not affected by the NK 1 receptor antagonist, spantide I (1 mg/kg), but were significantly reduced by the NK 2 receptor antagonist, GR159897 (1 mg/kg, Table 1 ). Repeated administration of LMN-NKA (10 or 30 μg/kg, everỹ 30-70 min) in SCI rats produced consistent bladder contractions (Fig. 2d) , suggesting no tachyphylaxis.
Drug-induced urine release in acute SCI rats (voiding cystometry)
To determine whether LMN-NKA can induce urine release in acute SCI rats, cystometry was performed while giving ascending doses of the drug, 0.1-300 μg/kg i.v., according to the protocol outlined in Fig. 1 . Acute SCI rats did not void with bladder filling, but instead began to leak when the maximal bladder pressure reached~35 mmHg (Fig. 3a white bar indicates the bladder pressure response at leak point pressure). At 70% bladder capacity, saline produced no pressure change or urine release, while LMN-NKA induced dose-dependent increases in bladder pressure (Fig. 3a) and urine release (Table 2) beginning at 1 μg/kg. Voiding efficiency also increased dose-dependently, reaching~50% at 300 μg/kg (Fig. 3b) . A separate, small group of rats (n = 4) were pretreated with the NK 2 receptor antagonist GR159897 (1 mg/kg) before a single dose of 30 μg/kg LMN-NKA. GR159897 (1 mg/kg) virtually abolished voiding in acute SCI rats (reducing voiding efficiency from 18.5 ± 17.8% to 0.75 ± 1.5%, n = 4; p < 0.05 paired Student's t test). Control voiding efficiency in response to 30 μg/kg LMN-NKA was lower in this small group than that observed in the doseresponse group (~35%, Fig. 3b ), presumably reflecting variability between animals and the small sample size (n = 4) for the antagonist experiments. Nevertheless, GR159897 (1 mg/kg) virtually abolished voiding in acute SCI rats.
Drug-induced voiding in intact rats at bladder volumes below micturition threshold
To determine whether LMN-NKA can induce voiding in intact rats, voiding cystometry was performed with ascending doses of the drug, 0.1-300 μg/kg i.v. according to the protocol outlined in Fig. 1 . With the bladder filled to 70% capacity, LMN-NKA induced dose-dependent increases in bladder pressure in all animals, up to 50-60 mmHg at a dose of 3 μg/kg, with no further increase at higher doses (Fig. 4a) . About half of animals voided when given 0.3 μg/kg LMN-NKA, and all animals voided at doses ≥10 μg/kg ( Table 2 ). The onset of voiding occurred about 30 s after drug administration. Voiding efficiency was greater than 70% at 10 μg/kg, with no further increase at higher doses (Fig. 4b) . Voiding efficiency during physiologically induced voiding, measured prior to drug dosing, was 72.00 ± 3.50% (n = 19 rats, white bar in Fig. 4b) . In a separate group of rats, GR159897 (1 mg/kg) abolished LNM-NKA (30 μg/kg)-induced VE in five out of six rats (from 84.86 ± 7.9 to 0 ± 0% n = 5, p < 0.05 paired Student's t test) and had no effect on n = 1 rat.
Effects on colonic activity
To determine whether LMN-NKA increases colonic activity, the effects of LMN-NKA on colorectal contractility were investigated in spinally intact and acute spinalized rats (Fig. 5) . Vehicle (i.v.) did not alter colorectal pressure. LMN-NKA (0.1-100 μg/ kg i.v.) produced a dose related increase in colorectal activity that occurred within 60 s of drug administration. No significant differences were seen between the intact and SCI rats; thus, the data were pooled for analysis. The AUC significantly increased with ascending doses, with doses of 1-100 μg/kg being significantly different compared to vehicle (one-way ANOVA followed by Dunnett's multiple comparison post-test, p < 0.05, Fig. 5 , n = 5-8 rats). Pretreatment with the NK 1 receptor antagonist, spantide I (1 mg/kg i.v.), did not reduce the effects of LMN-NKA (10 μg/kg i.v.) on colorectal activity. In contrast, pretreatment with the NK 2 receptor antagonist, GR159897 (1 mg/kg i.v.), virtually abolished tonic activity, and the effects of LMN-NKA (10 μg/kg i.v.) on colonic activity (Fig. 5c , n = 3 rats), consistent with the well-documented expression of NK 2 receptors in the circular smooth muscle of the gastrointestinal tract and their involvement in colonic activity (Carini et al. 2001; Lecci et al. 2004 Lecci et al. , 2006 Lordal et al. 1997 Lordal et al. , 2001 Mule et al. 2000; Warner et al. 2003) .
Other effects
Tachykinins have been involved in regulation of vascular tone and blood flow as well as modulation of blood pressure and heart rate, with most effects being attributed to the NK 1 receptors (Couture et al. 1989; Hoover et al. 2000; Longmore et al. 1997; Walsh and F McWilliams 2006) . There are numerous species differences in the expression of NK receptors, and in animal studies, the depth and type of anesthesia influence cardiovascular parameters, such that effects on blood pressure and heart rate measured under anesthesia are not necessarily reflective of the awake state. Therefore, we only assessed cardiovascular effects qualitatively. In these studies, doses ≥30 μg/kg produced inconsistent, small drops in blood pressure (≤10% change) with little change in heart rate. Further studies should be performed to determine any changes in blood pressure and heart rate in the conscious rat.
Tachykinins have been involved in bronchoconstriction, especially under inflammatory (asthma) conditions and the NK 2 receptor agonists have been shown to contract bronchiolar smooth muscle in various species (Advenier et al. 1992; Cohen et al. 2005; Floch et al. 1994; Joos et al. 2000; Naline et al. 1989 ). Thus, particular attention was focused on respiratory effects following in vivo administration of NK 2 receptor agonists. No significant drug-related changes in respiration and no labored breathing were observed. Fig. 3 Drug-induced urine release in acute SCI rats. a LMN-NKA produced a dose-dependent increase in the bladder pressure at which urine release was triggered. b LMN-NKA increased voiding efficiency in a dose-dependent manner. Asterisk indicates values significantly different from the vehicle (V) (p < 0.05, one-way ANOVA followed by Dunnett's multiple comparison post-test). F (8.54) = 18.98 for bladder pressure and F (8.64) = 7.661 for voiding efficiency. LPP stands for Bleak point pressure^and indicates parameters measured during bladder distention to full capacity (100%), when urine leaks occur in the absence of any drugs. Drugs were given when the bladder was at 70% capacity. Number of rats in each group = 12 (LPP), 9 (V), 4 (0.1 μg/kg), and 6-10 for 0.3-300 μg/kg Dose-related flushing of the extremities (ears, paws) was observed in both intact and acute SCI rats with doses greater than 3 μg/kg. Minor to moderate salivation and lacrimation were only observed with high doses (100-300 μg/kg). At doses of 3 and 10 μg/kg, which induced efficient voiding and/or urine release, these effects were absent or very mild.
Discussion
The results from these pharmacodynamic studies demonstrate that intravenous administration of a peptidergic NK 2 receptor agonist produces rapid-onset (<60 s), short-duration (<15 min) bladder contractions of sufficient power to induce Number of rats in each group = 8 (V), 5 (0.1 μg/kg), 6 (1 μg/kg), 8 (10 μg/kg), and 5 (100 μg/kg). V represents the baseline response in the absence of any drugs. c LMN-NKA-induced increase in colorectal activity is mediated via NK 2 receptors. Upper trace illustrates a control response to LMN-NKA (10 μg/kg; i.v.) given at the arrow. Lower trace illustrates lack of response to LMN-NKA (10 μg/kg; i.v.) when given 5 min after the NK 2 receptor antagonist, GR159897 (1 mg/kg, i.v.; n = 3 rats) Fig. 4 Drug-induced voiding at sub-threshold voiding volumes in intact rats. a LMN-NKA produced a dose-dependent increase in voiding bladder pressure. b LMN-NKA increased voiding efficiency in a dosedependent manner. Asterisk indicates values significantly different from the vehicle (V) (p < 0.05, one-way ANOVA followed by Dunnett's multiple comparison post-test). ANOVA F (8.72) = 25.88 for bladder pressure and F (8.62) = 14.26 for voiding efficiency. P stands for Bphysiological^and indicates parameters measured during bladder distention to full capacity (100%) in the absence of any drugs. Drugs were given when the bladder was at 70% capacity. Number of rats in each group = 19 (P), 12 (V), 4-8 for 0.1-300 μg/kg voiding in acute spinalized and spinal intact urethaneanesthetized rats. In acutely spinalized rats, doses of 10 μg/ kg and above produced urine release with a voiding efficiency of 30-50% at bladder pressures slightly higher than the leak point pressure. Although bladder pressure remained slightly elevated, urine voiding only lasted 1-3 min after drug administration. In rats with an intact spinal cord, LMN-NKA administration produced voiding that was as efficient as physiological voiding (~70% efficiency under urethane anesthesia) but with a higher micturition pressure, which may reflect small increases in urethral resistance (see below). The duration of action was relatively short (peak bladder pressure and voiding of urine decreased rapidly within 2 min post administration), and no tachyphylaxis was observed. Similar doses increased colorectal activity in acute spinalized and intact rats. Together, these results indicate that an agonist for the NK 2 receptor has the potential to trigger voiding and defecation after spinal cord injury.
The NK 2 receptors are expressed at several sites in the micturition pathways, including the detrusor smooth muscle (Burcher et al. 2000; Giuliani et al. 1993; Palea et al. 1996; Tramontana et al. 1998; Warner et al. 2003) , urethral smooth muscle (Palea et al. 1996) , afferent neurons (Maggi et al. 1986 (Maggi et al. , 1987 Morrison et al. 1999; Sculptoreanu et al. 2008 Sculptoreanu et al. , 2009 Sculptoreanu and de Groat 2003) , and possibly efferent neurons (Maggi et al. 1986; Tramontana et al. 1998) . Our data support the expression of functional receptors at these sites. The elevation in voiding pressure and leak point pressure in spinally intact and acute spinal animals, respectively, suggests that LMN-NKA is stimulating NK 2 receptors on both the detrusor and urethral smooth muscle. Indeed, urethral smooth muscles express NK 2 receptors that mediate contraction, but the potency and maximal efficacy of NK 2 receptor agonists to induce contraction is about ten times less in human urethra compared to human bladder (Palea et al. 1996) . It is relevant to note that, in spinally intact rats, the dose-response curves for bladder voiding pressure plateaued at 3 μg/kg, while bladder voiding efficiency continued to increase at 10 μg/kg (Fig. 4) . This suggests that bladder force continued to increase at 10 μg/kg, while urethral resistance did not. In the acute spinal rat, doses above 3 μg/kg produced both higher voiding efficiency and higher leak point pressures (Fig. 3) . This suggests that in the absence of neural control, increased drug doses are correlated with increases in both bladder and urethra contractions and that in the presence of neural control, reflex mechanisms may suppress urethral contractions (probably through nitrergic mechanisms) at higher doses.
Our data also support the conclusion that administration of an NK 2 receptor agonist triggers micturition reflexes in the spinally intact animal, by showing that LMN-NKA-induced voiding of urine at doses (0.3 μg/kg) that were below those that produced significant increases in bladder pressure in the acute spinal rat (1 μg/kg) (compare Figs. 3 and 4) . Because voiding efficiency was constant with increasing doses, it is tempting to speculate that LMN-NKA triggered activation of the supraspinal micturition, which then emptied the bladder to the same degree (~70%) as Bnatural^voiding that results from distension of the bladder sufficient to trigger the micturition reflex. Furthermore, our experimental observations (data not shown) show that voiding at these doses was accompanied by high frequency oscillations (HFOs) of bladder pressure, reflecting urethral rhabdosphincter contractions that accompany physiological voiding (i.e., activation of supraspinal micturition reflex pathways to the lower urinary tract). Thus, NK 2 receptor activation may Btrigger^micturition reflexes that reinforce bladder contractions, activate rhabdosphincter HFOs, and reduce urethral resistance. This triggering may result from stimulation of NK 2 receptors on afferent (and/or efferent) neurons or due to indirect activation of afferent terminals during bladder contractions subsequent to direct stimulation of NK 2 receptors on smooth muscle cells. The exact site of action and mechanisms remain to be further investigated. HFOs were absent from acute spinal rats, consistent with abolishment of micturition reflexes. Thus, in acute spinal rats, LMN-NKAinduced voiding appears to be due to direct stimulation of NK 2 receptors on detrusor smooth muscle, which was powerful enough to overcome urethral resistance.
LMN-NKA also increased colonic activity (Fig. 5) , consistent with the expression of NK 2 receptors in the smooth muscle of the colon and/or myenteric neurons, as reported in previous rodent and human studies (Carini et al. 2001; Lecci et al. 2004 Lecci et al. , 2006 Lordal et al. 1997 Lordal et al. , 2001 Mule et al. 2000; Warner et al. 2003) . Similar to the urethra, the NK 2 receptors are likely present in the internal anal sphincter (Tichenor et al. 2002) , where their activation may keep the sphincter tight, thus providing resistance to defecation. Future studies would need to investigate the role of these receptors in decreasing defecation efficiency and whether sphincter relaxants (such as phosphodiesterase inhibitors, topical diltiazem, a calcium channel blocker, botulinum toxin A injection and other) would provide additional benefits (Ballester et al. 2007; Gandomkar et al. 2015; Jones et al. 2002; Vaithianathan and Panneerselvam 2015) . While we did not assess defecation in this study, pilot studies in chronic SCI rats showed that LMN-NKA reliably induces defecation (in progress L. Marson), suggesting that if stools were present in the rectum, both urine and stools would be excreted (sitting on a toilet to urinate would be advisable).
Tachykinins have been implicated in the function and regulation of the cardiovascular and respiratory systems (Advenier et al. 1992; Cohen et al. 2005; Couture et al. 1989; Floch et al. 1994; Hoover et al. 2000; Joos et al. 2000; Longmore et al. 1997; Naline et al. 1989; Walsh and F McWilliams 2006) ; thus, cardiorespiratory effects of an NK 2 receptor agonists will need to be carefully investigated. In human volunteers, prolonged i.v. infusion of NKA (6, 12, 25, 50 pm/kg/min for 4 h) produced dose-dependent increases in gastrointestinal (GI) motility mediated by the NK 2 receptors with no significant changes in blood pressure or respiration in these subjects (Lordal et al. 1997 (Lordal et al. , 2001 Schmidt et al. 2003) . A small but significant change in heart rate was observed at 50 pm/kg/min for 4 h (Lordal et al. 1997 ) and 64 pm/kg/min for 5 min (Evans et al. 1988 ). Thus, even at maximal doses tested, intravenous NKA (which activates all NK receptors and is more selective for the NK 1 versus the NK 2 receptors) produced no significant changes in blood pressure or respiration in these subjects. Consistent with these studies, in anesthetized rats, non-significant fluctuations in arterial pressure were observed after dosing with LMN-NKA, indicating a cardiovascular study should be conducted in unanesthetized rats.
In the present study, no respiratory effects were observed following LMN-NKA administration. Furthermore, a recently completed GLP safety study conducted in awake rats, also showed no effects of LMN-NKA on respiration at doses below 100 μg/kg i.v. (unpublished results). One may be surprised at the absence of respiratory effects following systemic administration of NK 2 receptor agonists in rats and humans (Lordal et al. 1997 (Lordal et al. , 2001 Schmidt et al. 2003 ) since previous studies reported in vitro effects of NK 2 receptor agonists on respiratory smooth muscle in most species tested. However, even aerosol administration of NKA directly into the lungs produced no increase in bronchoconstriction in healthy subjects, and only mild, asymptomatic bronchoconstriction was produced in asthmatic patients (Advenier et al. 1992; Cohen et al. 2005; Evans et al. 1988; Floch et al. 1994; Joos et al. 2000; Naline et al. 1989) . This difference in sensitivity for asthmatic patients indicates that safety studies in this population, patients are warranted, but for most patients, respiratory effects do not seem to be a concern. In summary, it is unlikely that NK 2 receptor agonists will produce significant respiratory and cardiovascular effects at doses that will produce urination and defecation. However, these possible side effects remain to be carefully investigated in human.
Though future preclinical studies in animal models of chronic spinal cord injury are still needed to assess doses and routes of delivery, our results and previous studies indicate that a drug like LMN-NKA might offer a convenient method for inducing on-demand micturition and defecation in individuals with SCI.
Conclusion
Systemic administration of a peptidergic NK 2 receptor agonist triggered bladder contractions and urine release in both spinalized and intact rats when the bladder was filled to a sub-threshold voiding volume and induced powerful contractions of the colorectum. These results suggest that rapid-onset, short-duration, drug-induced voiding is possible in spinal and control rats with intravenous administration of an NK 2 receptor agonist. Further studies will extend these results to chronic SCI animal models as well as to translational studies focused on finding doses and routes of administration (e.g., sublingual or intranasal) that are convenient, safe, and efficacious. The development of pharmacological compounds that achieve efficient and effective bladder and colon emptying in individuals with SCI would greatly reduce medical complications associated with bladder and bowel management after SCI and greatly improve the quality of life of patients.
